![The sights of Avalon Air Show 2025: Day Three [PHOTOS]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/03/f-35-avalon-final-day-scaled-e1743079275404.jpg?#)
To approve Exelixis' Cabometyx in neuroendocrine tumors, FDA recognizes 'crossover impact' on survival
The FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. In an interesting item in the drug’s updated label, the FDA acknowledges the potential impact that control arm patient crossovers may have had on patient survival results.
The FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. In an interesting item in the drug’s updated label, the FDA acknowledges the potential impact that control arm patient crossovers may have had on patient survival results.
